Biopharma · FDA Approvals · Stock
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic con…
Assets on file: ADX-2191, ADX-629, reproxalap
Dated catalysts for ALDX, including recently decided ones.
Every first-hand event for ALDX, newest first.
ADX-2191 · NCT07402876 registry update
primary_completion: 2026-12 → 2029-12; completion: 2026-12 → 2029-12
ADX-629 · NCT05717920 registry update
primary_outcomes: ['Adverse Event (AE) Query'] → ['Number of Subjects With Serious Adverse Events']
Aldeyra Requests FDA Jurisdiction Transfer for ADX-2191 IND in PVRL and Withdraws SPA
Aldeyra requested transfer of the ADX-2191 IND for PVRL from the Division of Ophthalmology to the Division of Hematologic Malignancies 2 and withdrew the previously agreed SPA protocol. The regulatory path is now uncertain, the planned trial will not start, and the program must be redesigned, which may cause significant delays, higher costs, or prevent NDA resubmission and approval.
Aldeyra to Submit FDRR for Reproxalap in Dry Eye Disease
After three CRLs for the reproxalap NDA in dry eye disease, Aldeyra plans to file a Formal Dispute Resolution Request with the Office of New Drugs. The company expects to meet with OND in Q4 2026 to discuss the totality of evidence from nine trials, five of which met all primary endpoints.
Aldeyra to host reproxalap regulatory update webcast on Sep 29 2026
Aldeyra scheduled a webcast to provide a regulatory update focused on reproxalap for dry eye disease. The event itself does not alter the regulatory path or status of the asset.
Aldeyra plans Type D FDA meeting for reproxalap NDA resubmission
Aldeyra received FDA meeting minutes from a June 10, 2026 Type A meeting on potential NDA resubmission for reproxalap in dry eye disease. The company requested clarification of the minutes and intends to request a Type D meeting, expected by the end of Q3 2026, to discuss resubmission.
Aldeyra receives FDA CRL for reproxalap NDA in dry eye disease
The FDA issued a Complete Response Letter stating that the NDA lacks substantial evidence of efficacy in adequate and well-controlled studies for signs and symptoms of dry eye disease. No safety or manufacturing issues were identified. Aldeyra plans to request a Type A meeting within 30 days to discuss next steps toward potential approval.
Aldeyra Therapeutics, Inc. · complete response letter (NDA 216442)
FDA issued a complete response letter for NDA 216442 dated 2026-03-16.
Aldeyra: FDA extends reproxalap dry-eye NDA PDUFA to March 16, 2026
The FDA extended the PDUFA target action date for reproxalap’s NDA for dry eye disease from December 16, 2025 to March 16, 2026 after classifying the December 12, 2025 submission of the field-trial CSR as a major amendment. The extension provides the agency additional time to review the CSR and finalize labeling; no other deficiencies were identified at the December 12 meeting.
Aldeyra reports positive Phase 2 topline for ADX-629 in alcohol-associated hepatitis
ADX-629 met its primary objective, showing statistically significant improvements in MELD score, triglycerides, and CRP versus baseline in a 4-patient Phase 2 trial. Aldeyra is discontinuing further development of ADX-629 and redirecting resources to next-generation RASP modulators ADX-248 and ADX-246, extending cash runway into the second half of 2027.
Companies in the same sector closest to ALDX in market value.